Results 41 to 50 of about 73,039 (208)

Clinical significance of Janus Kinase inhibitor selectivity [PDF]

Rheumatology, 2018
Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: JAK1, JAK2, JAK3 and TYK2.
openaire   +3 more sources

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician

Journal of Family Medicine and Primary Care
Guidelines for primary care clinicians on monitoring and safety guidelines regarding Janus kinase and tyrosine kinase 2 inhibitors in the treatment of inflammatory skin conditions are often unclear.
Abigail Beard, Shannon C. Trotter
doaj   +1 more source

Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis [PDF]

, 2016
Background: Kinases are key mediators of inflammation, highlighting the potential of kinase inhibitors as treatments for inflammatory disorders. Selective kinase inhibitors, however, have proved disappointing, particularly in the treatment of rheumatoid ...
Biancheri, Paolo, Foster, Martyn R., Fyfe, Matthew C.T., MacDonald, Thomas T., Rowley, Adele, Sirohi, Sameer, Solanke, Yemisi, Walshe, Claire A., Webber, Steve, Wood, Eleanor   +9 more
core   +1 more source

Janus kinase inhibitors in the treatment of psoriatic arthritis

Современная ревматология, 2022
The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA ...
E. Yu. Loginova, T. V. Korotaeva
doaj   +1 more source

Janus kinase inhibitors - holistically seeing two faces

Australian Prescriber, 2015
Editor, - I was interested to read the recent article on Janus kinase inhibitors by Paul Kubler (Aust Prescr 2014;37:154-7). In addition to being pro-cancer, the Janus kinase-Signal Transducer and Activation of Transcription (JAK-STAT) pathway is part of a central physiological pro-survival mechanism.1 Thus pharmacological targeting of this signalling ...
John A Loudon, Paul Kubler
openaire   +2 more sources

Janus Kinase inhibitors in dermatology: a review

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2023
Janus Kinases (JAKs) are a subset of cytoplasmic protein tyrosine kinases (TYK), crucial for the initiation of signaling pathways activated by cytokines through phosphorylation and activation of the signal transducer and activator of transcription (STAT)
Bárbara Vieira-Granja, Sofia Magina
doaj  

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne

Acta Dermato-Venereologica, 2023
is missing (Short communication)
Fabienne Ballanger, Nicole Auffret, Marie-Thérèse Leccia, Jean Paul Claudel, Brigitte Dréno   +4 more
doaj   +1 more source

HiJAKing innate lymphoid cells? [PDF]

, 2017
The family of innate lymphoid cells (ILCs) consists of a heterogeneous group of cytokine-producing cells that have features in common with adaptive T helper (Th) cells.
Gadina, Massimo, Le, Mimi T, Sciume', Giuseppe   +2 more
core   +1 more source

Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy

Frontiers in Pharmacology
Disturbances in immunoregulation may lead to both cancer and autoimmune diseases. Many therapeutic drugs for autoimmune diseases also display anti-tumor efficacy.
Xiao-Huan Wei, Xiao-Huan Wei, Xiao-Huan Wei, Yuan-Yuan Liu, Yuan-Yuan Liu   +4 more
doaj   +1 more source